terazosin hydrochloride · Abbott · NDA 019057, 020347

Hytrin

Earliest generic entry, as listed · earliest of 4 marketed strengths
Open now

No marketed reference-listed strength; date taken from all listed strengths.

No unexpired patents or exclusivities are listed for this product.

Listed patents · 0 unexpired

No unexpired patents listed.

Exclusivities · 0 unexpired

No unexpired exclusivities listed.

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.

Products covered · 8

NDA · productFormStrengthListed expiry
019057 · 001 · discontinuedtablet, oralEQ 1MG BASEopen
019057 · 002 · discontinuedtablet, oralEQ 2MG BASEopen
019057 · 003 · discontinuedtablet, oralEQ 5MG BASEopen
019057 · 004 · discontinuedtablet, oralEQ 10MG BASEopen
020347 · 001 · RLD · discontinuedcapsule, oralEQ 1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**open
020347 · 002 · RLD · discontinuedcapsule, oralEQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**open
020347 · 003 · RLD · discontinuedcapsule, oralEQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**open
020347 · 004 · RLD · discontinuedcapsule, oralEQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**open